Kumar Neil's Form 4 filing
BridgeBio Pharma, Inc. (BBIO) · filed Nov 10, 2025
- Accession no.
- 0001470831-25-000302
- Filed
- Nov 10, 2025
- Trade date
- Nov 6-7, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 12 non-derivative transactions. Open-market sales total $4.98M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kumar NeilCIK 0001742485 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 6, 2025 | Common Stock | SSaleDisposed | −12,576 | $62.91F2 | −$791,156.16 | 4,625,871 | Indirect | |
| Nov 6, 2025 | Common Stock | SSaleDisposed | −7,324 | $63.55F4 | −$465,440.2 | 4,618,547 | Indirect | |
| Nov 6, 2025 | Common Stock | SSaleDisposed | −100 | $64.39 | −$6,439 | 4,618,447 | Indirect | |
| Nov 7, 2025 | Common Stock | SSaleDisposed | −12,492 | $61.14F5 | −$763,760.88 | 4,605,955 | Indirect | |
| Nov 7, 2025 | Common Stock | SSaleDisposed | −7,308 | $61.87F6 | −$452,145.96 | 4,598,647 | Indirect | |
| Nov 7, 2025 | Common Stock | SSaleDisposed | −200 | $62.81F7 | −$12,562 | 4,598,447 | Indirect | |
| Nov 6, 2025 | Common Stock | SSaleDisposed | −12,529 | $62.91F2 | −$788,199.39 | 823,157 | Indirect | |
| Nov 6, 2025 | Common Stock | SSaleDisposed | −7,371 | $63.56F4 | −$468,500.76 | 815,786 | Indirect | |
| Nov 6, 2025 | Common Stock | SSaleDisposed | −100 | $64.39 | −$6,439 | 815,686 | Indirect | |
| Nov 7, 2025 | Common Stock | SSaleDisposed | −12,234 | $61.13F8 | −$747,864.42 | 803,452 | Indirect | |
| Nov 7, 2025 | Common Stock | SSaleDisposed | −7,546 | $61.87F9 | −$466,871.02 | 795,906 | Indirect | |
| Nov 7, 2025 | Common Stock | SSaleDisposed | −220 | $62.79F10 | −$13,813.8 | 795,686 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price of the shares sold from $62.245 to $63.24 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Referenced by the price of 2 transactions in Table I.
- F4
Represents the weighted average sale price of the shares sold from $63.25 to $64.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Referenced by the price of 2 transactions in Table I.
- F5
Represents the weighted average sale price of the shares sold from $60.59 to $61.58 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F6
Represents the weighted average sale price of the shares sold from $61.59 to $62.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F7
Represents the weighted average sale price of the shares sold from $62.78 to $62.83 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F8
Represents the weighted average sale price of the shares sold from $60.57 to $61.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F9
Represents the weighted average sale price of the shares sold from $61.58 to $62.37 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F10
Represents the weighted average sale price of the shares sold from $62.68 to $62.83 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.